Streetbeat News

Stock Prices

EXK

Endeavour Silver shares are trading lower after the company announced a significant equipment failure at the Guanacevi mill, leading to a suspension of material processing for up to 12 weeks.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:05 pm

TSHA

Taysha Gene Therapies (NASDAQ:TSHA) reported Q2 2024 GAAP EPS of $(0.09), beating the $(0.10) estimate, but missed sales estimates with $1.112M against the expected $2.664M.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:05 pm

PXS

Pyxis Tankers (NASDAQ:PXS) reported Q2 2024 earnings of $0.43 per share and sales of $13.910 million, beating the analyst consensus estimate of $13.290 million. This represents a 46.34% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:03 pm

TNXP

Tonix Pharmaceuticals presented positive Phase 3 trial data for TNX-102 SL, showing significant improvements in fibromyalgia pain and sleep quality. The FDA has granted Fast Track designation, with an NDA submission expected in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:01 pm

YMAB

Y-mAbs Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results and issued FY24 total net revenue guidance with its midpoint below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:01 pm

K

Over the past three months, 13 analysts have evaluated Kellanova (NYSE:K), showing a range of sentiments from bullish to bearish. The average 12-month price target has increased to $67.38, reflecting a 7.52% rise from the previous target. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Despite a recent revenue decline of -4.74%, Kellanova maintains strong profitability with a net margin of 10.78% and a high ROE of 10.65%. However, the company has a high debt-to-equity ratio of 1.97, indicating higher financial risk.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 12:00 pm

JILL

Four analysts have provided ratings for J.Jill (NYSE:JILL) in the latest quarter, showing a mix of bullish and bearish perspectives. The average 12-month price target is $42.25, with a high of $44.00 and a low of $37.00. This reflects an 11.18% increase from the previous average price target of $38.00. Analysts have highlighted J.Jill's strong financial performance, including a 7.5% revenue growth rate, a 10.34% net margin, a 36.97% ROE, and a 3.83% ROA. However, the company faces challenges with a high debt-to-equity ratio of 5.46.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 12:00 pm

LLY

Analysts' ratings for Eli Lilly (NYSE:LLY) over the last quarter show a range of sentiments from bullish to bearish. The average 12-month price target has increased by 5.3% to $955.64. Key analysts have raised their price targets, reflecting positive expectations for the company's performance.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 12:00 pm

BNS

KEY

KeyCorp (NYSE:KEY) shares are trading higher after announcing a strategic minority investment agreement with The Bank of Nova Scotia (NYSE:BNS). Scotiabank will invest approximately $2.8 billion in KeyCorp, acquiring about 14.9% of common stock at $17.17 per share. This investment is expected to boost KeyCorp’s CET1 capital ratio and tangible book value per share, and enhance profitability and capital strength. The initial purchase is expected to close by the end of August, with the additional purchase anticipated in the first quarter of 2025.

Portfolio Pulse from Lekha Gupta

August 12, 2024 | 11:59 am

RVNC

Trading for RVNC was halted at 7:55:00 a.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:55 am